News
Recent news about Panacea Venture and select portfolio companies
Evox Therapeutics Expands Scientific Advisory Board
Additional world-leading expertise stands to further accelerate the Company’s pipeline programs targeting rare neurodegenerative diseases
Evox Therapeutics Expands Scientific Advisory Board
Additional world-leading expertise stands to further accelerate the Company’s pipeline programs targeting rare neurodegenerative diseases
TPEx-Listed HanchorBio Advances Global Impact of HCB101 Immunotherapy
TAIPEI, SHANGHAI and SAN FRANCISCO, July 16, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827.TWO), a pioneer of immunotherapy biologics, is announcing its official listing on the Taipei Exchange (TPEx) Emerging Stock Board under the ticker symbol 7827.TWO and the name Hanchor-KY
TPEx-Listed HanchorBio Advances Global Impact of HCB101 Immunotherapy
TAIPEI, SHANGHAI and SAN FRANCISCO, July 16, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827.TWO), a pioneer of immunotherapy biologics, is announcing its official listing on the Taipei Exchange (TPEx) Emerging Stock Board under the ticker symbol 7827.TWO and the name Hanchor-KY
Myrtelle Launches Commercial Manufacturing First-in-Class Gene Therapy
Myrtelle Launches Commercial-Stage Manufacturing of First-in-Class Gene Therapy for Canavan Disease.
Myrtelle Launches Commercial Manufacturing First-in-Class Gene Therapy
Myrtelle Launches Commercial-Stage Manufacturing of First-in-Class Gene Therapy for Canavan Disease.
Revolutionizing the Canavan Disease Treatment Market
Canavan disease, a rare and fatal neurological disorder caused by a mutation in the ASPA gene, leads to a deficiency in the enzyme aspartoacylase.
Revolutionizing the Canavan Disease Treatment Market
Canavan disease, a rare and fatal neurological disorder caused by a mutation in the ASPA gene, leads to a deficiency in the enzyme aspartoacylase.
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections.
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections.